1-(3-hydroxy-4-methoxyphenyl)-2-hydroxyethanone | 90536-46-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(3-hydroxy-4-methoxyphenyl)-2-hydroxyethanone
• 英文别名: ω.3-Dihydroxy-4-methoxy-acetophenon；2-hydroxy-1-(3-hydroxy-4-methoxy-phenyl)-ethanone；2-Hydroxy-1-(3-hydroxy-4-methoxy-phenyl)-aethanon；2-Hydroxy-1-(3-hydroxy-4-methoxyphenyl)ethanone
• CAS: 90536-46-2
• 化学式: C₉H₁₀O₄
• 分子量: 182.176
• InChiKey: MNKDIXCAZXQWMM-UHFFFAOYSA-N

物化性质

• 熔点：
  177–178°C
• 沸点：
  395.2±32.0 °C(Predicted)
• 密度：
  1.292±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-Methoxy-3-acetoxy-ω-diazo-acetophenon 在 盐酸 作用下， 生成 1-(3-hydroxy-4-methoxyphenyl)-2-hydroxyethanone
  参考文献：
  名称：

  «物质Z»。关于肾上腺皮质成分及相关物质第100部分

  摘要：

  «替代的隔离。描述了来自肾上腺提取物的Z»。发现该物质与4，ω-二羟基-3-甲氧基-苯乙酮相同，后者以纯结晶形式合成用于比较。表格已准备好。描述了位置异构体3，ω-二羟基-4-甲氧基-苯乙酮（“ Iso-Iso-Z”）的合成。

  DOI：

  10.1002/hlca.19590420610

文献信息

• Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
  申请人：——

  公开号：US20030087922A1

  公开（公告）日：2003-05-08

  The present invention provide a compound of formula I or II: 1 or a pharmaceutically acceptable derivative thereof, wherein R 1 , R 2 , R 3 , and R 4 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli; and Src-family kinases, especially Src and Lck kinases. These compounds are also inhibitors of GSK3 and CDK2 kinases. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.

  本发明提供了化合物I或II的化合物： 或其药学上可接受的衍生物，其中R 1 ，R 2 ，R 3 和R 4 如规范中所述。这些化合物是蛋白激酶的抑制剂，特别是JNK的抑制剂，JNK是一种参与细胞增殖、细胞死亡和对细胞外刺激反应的哺乳动物蛋白激酶；以及Src家族激酶，特别是Src和Lck激酶。这些化合物还是GSK3和CDK2激酶的抑制剂。本发明还涉及生产这些抑制剂的方法。本发明还提供了包括本发明的抑制剂的药物组合物以及利用这些组合物在治疗和预防各种疾病中的方法。
• Synthesis and anti-inflammatory activity of isoquebecol
  作者：Sébastien Cardinal、Pierre-Alexandre Paquet-Côté、Jabrane Azelmat、Corinne Bouchard、Daniel Grenier、Normand Voyer

  DOI：10.1016/j.bmc.2017.01.050

  日期：2017.4

  We report here the synthesis of isoquebecol, an unprecedented constitutional isomer of quebecol, a polyphenolic compound discovered in maple syrup. The methodology used to prepare isoquebecol involves, as key steps, the formation of a dibromoalkene from an α-ketoester precursor, followed by a double Suzuki-Miyaura reaction. The anti-inflammatory activity of isoquebecol was studied on macrophage cells

  我们在这里报告了异方苯酚的合成，异方苯酚是枫糖浆中发现的多酚化合物quebecol的前所未有的结构异构体。制备异白酚的方法学涉及关键步骤，即由α-酮酸酯前体形成二溴代烯烃，然后进行Suzuki-Miyaura双反应。通过监测其抑制LPS诱导的IL-6分泌的能力，研究了异黄柏对巨噬细胞的抗炎活性。结果表明，这种新化合物具有比其天然异构体更高的生物活性。这项研究中还制备了quebecol，异quebecol和模型类似物2,3,3-三苯丙醇的前体和衍生物。
• Isoquinoline Derivatives, Methods of Synthesis and Uses Thereof
  申请人：Prosetta Biosciences, Inc.

  公开号：US20210403477A1

  公开（公告）日：2021-12-30

  Described herein are compounds, pharmaceutical compositions and methods of using these compounds and pharmaceutical compositions for treating and/or preventing conditions such as amyotrophic lateral sclerosis. These compounds and pharmaceutical compositions are also useful as antivirals and antimicrobial agents.

  本文描述了化合物、药物组合物以及使用这些化合物和药物组合物治疗和/或预防条件，如肌萎缩侧索硬化症。这些化合物和药物组合物还可用作抗病毒和抗微生物药剂。
• MPSC6 binuclear complexes immobilized on graphene oxide for oxidation of lignin model compounds and lignin
  作者：Xue-Fei ZHOU、Zheng-Rong ZOU、Xiao-Jun YANG

  DOI：10.33224/rrch.2020.65.11.02

  日期：——

  An efficient process for the oxidative degradation of lignin using M-GO (MPSC6 binuclear complexes immobilized on graphene oxide) biomimetic catalysts in acetonitrile was developed in this work. Different M-GO catalysts (M=Co, Cu, Zn and Ni) were used to catalyze the depolymerization of lignin model compounds and organosolv lignin. The results showed that the immobilization of MPSC6 complexes on GO was favorable for regulating the valuable depolymerization of the model compounds and lignin. The optimal solid catalyst Co-GO exhibited high catalytic activity, which showed a 83.04% conversion of phenolic β-O-4 lignin model compound, a 91.26% conversion of veratryl alcohol and a 96.24% conversion of vanillyl alcohol with a catalyst/model compound ratio of 50 mg:10 mmol and a dosage of 15 mmol H2O2 at 80 °C for 3 h. The stuctural changes of organosolv lignin occurred in catalytic oxidation were analyzed in terms of O/C ratio, molecular weight and OH content of lignin samples, and a plausible mechanism involving the formation of aromatic products and muconolactone from lignin depolymerization over M-GO was also proposed.

  在这项工作中，开发了一种利用M-GO（在氧化石墨烯上固定的MPSC6双核复合物仿生催化剂）在乙腈中高效降解木质素的过程。使用不同的M-GO催化剂（M=Co、Cu、Zn和Ni）催化降解木质素模型化合物和有机溶剂木质素。结果显示，将MPSC6复合物固定在GO上有利于调节模型化合物和木质素的有价值降解。最佳固体催化剂Co-GO表现出高催化活性，对酚类β-O-4木质素模型化合物转化率为83.04％，对维拉特醇的转化率为91.26％，对香草醇的转化率为96.24％，催化剂/模型化合物比为50 mg:10 mmol，过氧化氢用量为15 mmol，在80℃下反应3小时。对有机溶剂木质素在催化氧化中发生的结构变化进行了分析，包括木质素样品的O/C比、分子量和OH含量，并提出了一个涉及在M-GO上木质素降解形成芳香产物和丁二酮内酯的合理机制。
• INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1373257A1

  公开（公告）日：2004-01-02